Vesigen Therapeutics

Overview
News
Human Gene Editing?
Product stageSegments
Seed
?
Diagnostic and delivery systems
?

Vesigen Therapeutics develops novel drug delivery technologies based on ARRDC1-mediated microvesicles (ARMM)—a class of extracellular vesicles produced by cells to carry communication signals to and from cells and tissues—to facilitate medicine delivery to intracellular therapy targets, with primary focus on neurological diseases, oncology, and ophthalmology. The ARRMMed particles have the ability to deliver ribonucleic acid (RNA), proteins, and gene editing complexes directly into the cell’s cytoplasm (the content inside a cell) without harming the therapeutic cargo while being transported as opposed to other technologies such as endocytosis—a natural delivery mechanism. The company also offers engineered vesicles to other pharmaceutical and biotech companies to target their desired disease indications. 

Funding and financials

The Harvard University spin-out launched in July 2020 with USD 28.5 million in Series A funding led by Leaps by Bayer and Morningside Ventures. The proceeds were earmarked to fund the development of its platform and advance its preclinical and clinical development efforts. 

HQ location:
One Kendall Square Building 200, Suite 001 Cambridge MA USA
Founded year:
2019
Employees:
1-10
IPO status:
Private
Total funding:
USD 28.5 mn
Last Funding:
-
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.